Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

Hepatology

Volumn 64, Issue 6, 2016, Pages 2038-2046

  Calderaro, Julien ^a,b,c   Rousseau, Benoît ^a,b,c   Amaddeo, Giuliana ^a,b,c   Mercey, Marion ^b   Charpy, Cécile ^a   Costentin, Charlotte ^a   Luciani, Alain ^a,b,c   Zafrani, Elie Serge ^a   Laurent, Alexis ^a   Azoulay, Daniel ^a,c   Lafdil, Fouad ^b,c   Pawlotsky, Jean Michel ^a,b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; BIOLOGICAL MARKER; CYTOKERATIN 19; GLUTAMATE AMMONIA LIGASE; PROGRAMMED DEATH 1 LIGAND 1; WNT PROTEIN; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ALCOHOL CONSUMPTION; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; FEMALE; HEMOCHROMATOSIS; HEPATITIS B; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION RISK; INFLAMMATORY CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; LIVER NEOPLASMS; METABOLISM;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 84982913900     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28710     Document Type: Article

References (34)

1. Wang H, Liddell CA, Coates MM, Mooney MD, Levitz CE, Schumacher AE, et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:957–979.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–E386.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–1127.
4. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
6. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–461.
7. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311–319.
8. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–2465.
9. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–562.
10. El-Khoueiry AB, Melero I, Crocenzi T, Welling T, Cheung Yau T, Yeo W, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC) [Abstract]. J Clin Oncol 2015;33(Suppl.):LBA101.
11. Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol 2014;290:72–79.
12. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
13. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity. Nat Med 2003;9:562–567.
14. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
15. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847–856.
16. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15:971–979.
17. Bosman FT; World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: International Agency for Research on Cancer; 2010.
18. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus–related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010;34:1630–1636.
19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–293.
20. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49:138–151.
21. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410–416.
22. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with “stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011;54:1707–1717.
23. Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, Yoo JE, et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial–mesenchymal transition. Hepatology 2012;55:1776–1786.
24. D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015;46:357–365.
25. Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 2015;51:421–426.
26. Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 2016;47:52–63.
27. Patel KR, Liu TC, Vaccharajani N, Chapman WC, Brunt EM. Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases. Arch Pathol Lab Med 2014;138:1193–1202.
28. Chan AW, Tong JH, Pan Y, Chan SL, Wong GL, Wong VW, et al. Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. Am J Surg Pathol 2015;39:304–312.
29. Solinas A, Calvisi DF. Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas. World J Gastroenterol 2015;21:3472–3479.
30. + dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011;186:6905–6913.
31. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015;21:24–33.
32. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505–511.
33. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, et al. Immune suppression and resistance mediated by constitutive activation of Wnt/beta-catenin signaling in human melanoma cells. J Immunol 2012;189:2110–2117.
34. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231–235.